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Abstract
Introduction The urinary level of the type II collagen degradation
marker CTX-II is increased in postmenopausal women and in
ovariectomised rats, suggesting that oestrogen deprivation
induces cartilage breakdown. Here we investigate whether this
response to oestrogen is also true for other type II collagen
turnover markers known to be affected in osteoarthritis, and
whether it relates to its presence in specific areas of cartilage
tissue.
Methods The type II collagen degradation markers CTX-II and
Helix-II were measured in the body fluids of premenopausal and
postmenopausal women and in those of ovariectomised rats
receiving oestrogen or not. Levels of PIIANP, a marker of type II
collagen synthesis, were also measured in rats. Rat knee
cartilage was analysed for immunoreactivity of CTX-II and
PIIANP and for type II collagen expression.
Results As expected, urinary levels of CTX-II are significantly
increased in postmenopausal women and also in oestrogen-
deprived rats, although only transiently. However, in neither case
were these elevations paralleled by a significant increase of
Helix-II levels and PIIANP levels did not change at any time. CTX-
II immunoreactivity and collagen expression were detected in
different cartilage areas. The upper zone is the area where CTX-
II immunoreactivity and collagen expression best reflected the
differences in urinary levels of CTX-II measured in response to
oestrogen. However, correlations between urinary levels of
CTX-II and tissue immunostainings in individual rats were not
statistically significant.
Conclusions We found only a small effect of oestrogen
deprivation on cartilage. It was detected by CTX-II, but not by
other type II collagen turnover markers typically affected in
osteoarthritis.
Introduction
The molecular mechanism of osteoarthritis (OA) development
is poorly understood. Cartilage alterations in the joint start very
locally, extend progressively and lead to inflammation [1]. Sev-
eral studies have suggested that changes in the cartilage
occur well before damage to the cartilage matrix can be
detected, and that they are related to modifications in the
metabolism of type II collagen and proteoglycans [2-5]. The
trigger switching the chondrocyte to a pathological state has,
however, not been identified.
OA has multiple aetiologies, but is most often believed to
result from mechanical injuries. There are also suggestions
that oestrogen deprivation favours OA development [6]. This
hypothesis was first suggested by epidemiological studies
showing that menopause coincides with the appearance of
many of the symptoms associated with OA (i.e. marked inci-
dence of knee OA at menopause compared with men of simi-
lar age), and that hormone replacement therapy influences the
disease activity [7-10]. The hypothesis was also supported by
the fact that chondrocytes have oestrogen receptors [11,12],
Bp: base pair; CTX-II: C-terminal telopeptide of type II collagen; ELISA: enzyme-linked immunosorbant assay; H&E: haematoxylin and eosin; OA: oste-
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and that long-term oestrogen replacement therapy has a chon-
droprotective effect in monkeys [13]. Recently, strong support
for this hypothesis came from the development of diagnostic
tools to allow monitoring of cartilage degradation in a dynamic
way. Thus, it was found that menopause coincides with an
increase in the urinary levels of CTX-II, a fragment of type II col-
lagen originating from its telopeptide region, and that this
increase correlates with joint damage and is antagonised by
oestrogen [14-16]. In order to experimentally test the hypoth-
esis that oestrogen deprivation may favour OA development,
rat ovariectomy experiments were performed. They showed
that ovariectomy increases the levels of CTX-II in urine, and
may induce mild lesions in the articular cartilage [17].
However, despite all these data, the relevance of CTX-II to car-
tilage turnover in post-menopausal-like situations has not been
definitively demonstrated, and a number of questions still need
to be answered. The ovariectomy-induced increase in CTX-II
level in the rat experiments is transient: it occurs two to four
weeks after ovariectomy and decreases after about six weeks.
This transitory increase in CTX-II contrasts with the permanent
ovariectomy-induced increase in CTX-I, a type I collagen deg-
radation marker reflecting bone resorption [17]. At first sight,
this observation would mean that the effect of oestrogen dep-
rivation is permanent on bone, but not on cartilage; however,
the reason for this difference is unclear.
It is surprising that elevated levels of CTX-II drop not only in
response to oestrogen and related agents, but also in
response to bone resorption inhibitors not expected to affect
cartilage, such as bisphosphonates [18,19]. Presently, CTX-II
is the only cartilage degradation marker that has been investi-
gated in response to oestrogen deprivation, and it would
therefore be interesting to investigate whether oestrogen dep-
rivation similarly affects other type II collagen degradation
markers, such as Helix-II, which corresponds to a fragment
originating from the helicoidal part of type II collagen [20].
The interest of comparing CTX-II and Helix-II is also stressed
by the fact that, despite both being elevated in OA patients,
their levels in the body fluids do not correlate strictly with each
other, and their immunoreactivity distributes differently across
different histological areas of OA knees [20,21]. This differ-
ence suggests that the markers may reflect different collagen-
olytic pathways, which possibly respond differently to
oestrogens. Presently, the effect of oestrogen deprivation on
CTX-II is based essentially on assessment of its urinary levels,
and it has not been systematically analysed if these urinary lev-
els reflect the local cartilage events where CTX-II originates
from. Cartilage sections have indeed been examined only at
late time points when CTX-II levels of ovariectomy-rats were
back to the control levels of sham-operated rats.
The present study aims to investigate the relevance of CTX-II
to cartilage collagen metabolism in situations of oestrogen
deprivations, and addresses therefore several of the above
questions. First it extends CTX-II to Helix-II measurements
both in pre- and post-menopausal women and in rats after ova-
riectomy treated or not with oestrogen. It also investigates
whether these collagen degradation products may relate to
the breakdown of newly synthesised collagen, because colla-
gen synthesis is reported to be upregulated in OA [22-24].
PIIANP, the fetal propeptide, appeared to be an especially rel-
evant marker of OA [22,25]. Second, our present study
extends body fluid measurements of CTX-II to immunostain-
ings of CTX-II in knee cartilage of ovariectomised rats, by ana-
lysing cartilage sections from ovariectomised rats at early time
points where CTX-II is increased compared with sham-oper-
ated rats. Whether oestrogen deprivation induces lesions in
the cartilage, as well as collagen synthesis is also examined.
Materials and methods
Healthy premenopausal and postmenopausal women
Fifty healthy premenopausal women (age 30 to 40 years,
mean age 35 years) and 50 healthy untreated postmenopau-
sal women (age 48 to 73 years, mean age 59 years) were
included in the study. None of the patients had symptomatic
OA, and this was confirmed by WOMAC index (Western
Ontario and McMaster Universities index of arthritis) and radi-
ography. Serum samples from a biobank in Lyon, where all par-
ticipants had signed an informed consent allowing the use for
scientific purposes, were used. The use of the biobank was
approved by local French authorities for the use of biomarker
measurement. All premenopausal women had regular cyclic
menses. All postmenopausal women had been amenorrhoeic
for at least five years. All pre- and postmenopausal women
were healthy with no disease or treatment that may interfere
with bone and cartilage metabolism including oestrogen
replacement therapy in postmenopausal women. For all
women a fasting serum sample collected before 9 am and a
second morning void urine sample were collected and stored
below -70°C until ready for assay for urinary CTX-II and urinary
Helix-II.
Ovariectomy rat model design
The rat ovariectomy protocol was approved by the Danish
Experimental Animal Inspectorate under the Ministry of justice
(jour. no. 2003/561-795). Sixty acclimated, female virgin,
seven-month-old Sprague-Dawley rats (Charles River Labora-
tory, Kisslegg, Germary) were maintained under standard con-
ditions of 12-hour day and night cycles. Rats were given
common chow (Altromin 1314, Brogaarden A/S, Denmark)
and water ad libitum. Three to four rats were kept together in
cases and cared for daily by an animal technician. Rats of
seven months of age were used to reduce the release of CTX-
II from the growth plate into the body fluids as much as possi-
ble [17]. Rats were then randomised to two equal size groups
assigned to a two-week (A) and six-week (B) experiment. Rats
of these two groups were further divided randomly into three
subgroups: eight rats for sham operation (Sham), 11 rats forAvailable online http://arthritis-research.com/content/11/1/R9
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ovariectomy plus oestradiol (OVX+oestradiol) and 11 rats for
ovariectomy plus placebo (OVX+placebo), giving a total of 30
rats in each group.
Rats were premedicated with 5 mg/kg midazolam (Dormicum,
Hameln pharmaceuticals, Hameln, Germany) subcutaneously
and anaesthetised with 4% isoflurane (Abbott, Gentofte, Den-
mark) in air. After surgery the animals were given 0.05 mg/kg
buprenophin (Temgesic, Schering-Plough A/S, Ballerup, Den-
mark) subcutaneously and this dose was also given twice a
day for two days.
Ovariectomy was performed using a dorsal midline incision
and the entrance into the abdominal cavity was made with a
small cut in to the muscle half to two-thirds of the way down
the side of the rat. The ovaries were pulled out through the
muscle incision by grasping the periovarian fat, and the ovaries
were removed with a single cut. The uterus was returned into
the abdominal cavity. The skin incision was sutured using
absorbable sutures.
At surgery, a 60-day slow release pellet containing either pla-
cebo or 0.05 mg 17α-ethylenestradiol (Innovative Res. of
America, Sarasota, FL, USA) was implanted subcutaneously.
Four rats died prematurely immediately after ovariectomy: from
group A, one OVX+oestradiol and two OVX+placebo rats;
from group B, one OVX+oestradiol rat. An additional
OVX+placebo rat was excluded from group A, because it
failed to urinate at given time points. Final numbers of rats
included in the study are given in Table 1. Urine and serum
samples were collected before surgery (baseline, t = 0 weeks)
and thereafter every second week (Figure 1). Urine collection
was achieved by spotting for up to two hours in clean grid bot-
tom cages and serum was taken from ocular blood (retro-
orbital; Figure 1). The body weight (Table 1) and health status
of the rats were recorded every week. Group A and B rats
were euthanased after two (group A) and six weeks (group B),
respectively.
The left hind leg from each rat were fixed in formalin for 48
hours at room temperature, and decalcified in 7% idranal
(Riedel-van Häen, Sigma-Aldrich, Glostrup, Denmark) for
three to four weeks depending on individual knee. Decalcified
knees were cleaved into about two sections using the medial
collateral ligament as a guide. These two pieces were paraffin-
embedded, and then sectioned parallel to this cleavage plane
until the central area of the medial tibia plateau was reached,
as previous studies showed the prevailing interest of this area
[17,26].
Measurement of biomarkers CTX-II, PIIANP and Helix-II 
in body fluids
Urinary CTX-II was measured with a competitive ELISA (Carti-
Laps, IDS Nordic, Denmark) based on a mouse monoclonal
antibody raised against the EKGPDP sequence of human and
rat type II collagen C-telopeptide. This sequence is specific for
the C-telopeptide of type II collagen. Intra- and inter-assay CVs
(coefficient of variation) were lower than 8% and 15%, respec-
tively [15]. CTX-II measurements were corrected for the uri-
nary creatinine level and measured by a colorimetric assay
[27]. Rat serum CTX-II could not be measured in the current
study. Serum PIIANP was measured by an ELISA [23] using
polyclonal antibodies raised against recombinant GST-human
type II procollagen exon 2 fusion protein [28], and which
cross-react with rat type II procollagen. It was not possible to
measure PIIANP because of the lack of human serum. Helix-II
was measured by a competitive ELISA (Syncart, Synarc, Lyon,
France) based on a rabbit polyclonal antibody raised against
the amino acid 622–632 sequence of the α1 chain of human
and rat type II collagen. Intra- and inter-assay variations (CVs)
were lower than 9% and 14%, respectively [20]. Serum levels
of Helix-II were measured in rats, and urinary levels were meas-
ured in humans, because of the limited sample availability of
human serum. Raw data from individual rats at two (group A),
four and six (group B) weeks were baseline-corrected by sub-
tracting baseline (time 0) followed by division by the baseline
values, and finally multiplying by 100% to give the percentage
difference from baseline.
Figure 1
Experimental flow diagram of the ovariectomy rat experiment Experimental flow diagram of the ovariectomy rat experiment. Blood and urine samples were isolated at day of ovariectomy (t = 0 weeks) and at two, 
four and six weeks after ovariectomy. Group A was terminated two weeks post-ovariectomy and group B six weeks post-ovariectomy.Arthritis Research & Therapy    Vol 11 No 1    Bay-Jensen et al.
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Histopathological assessment of the rat knees
Previous studies have shown that ovariectomy-induced altera-
tions in rat knee cartilage mainly affected the medial tibia pla-
teau [17,26], so we obtained two 5 μm sections
representative of this area, that were 80 to 100 μm apart.
These sections were mounted on positive loaded glass slides
(Superfrost plus, Hounisen, Denmark). Sections were then
deparaffinised and rehydrated. One slide was taken for histol-
ogy and several slides were used for immunohistochemistry.
Slides for histology were stained with a standard Fast green-
Safranin O trichrome protocol [29]. A modified Colombo
score was used to assess the degree of possible damage
where scores of 0, 1 or 2 was given for the 10 different path-
ological features: loss of superficial layer; erosion; fibrillation;
cyst; osteophyte; loss of proteoglycan; disorganisation of
chondrocytes; clonal chondrocytes; exposure of subchondral
bone; subchondral vascularisation. Colombo score normally
consists of scores 0 to 4, but our previous experience with the
ovariectomised rat model at the given time points led us to
simplify the scoring system, so that only scores 0, 1 and 2
were given, and defined as follows: 0 = the feature was not
observed; 1 = the feature was observed, but was weak; 2 =
the feature was pronounced and well-defined. The sections
were analysed blindly.
Immunohistochemistry
Rehydrated sections, adjacent to the ones used for histologi-
cal analysis, were demasked in Target retrieval buffer® (Dako,
Glostrup, Denmark) at a pH of 6.0 overnight at 63°C. Sections
were then incubated with a peroxidaxe blocking reagent®
(Dako, Glostrup, Denmark) for 10 minutes and with 0.5%
Casein (Sigma-Aldrich, Denmark) in Tris-buffered saline (TBS)
for 20 minutes, both at room temperature. After blocking, sec-
tions were incubated with either rabbit anti CTX-II (1:3000),
rabbit anti PIIANP (1:1500) or their respective preimmune
sera overnight at 4°C. Antibodies used have previous been
described [21]. Of note was that PIIANP recognises the N-ter-
minal pro-peptide of type IIA collagen both as part of the pro-
protein and in its cleaved form [22]. Bound antibodies were
then cross bound to the polymer reagent Envision+ anti-rabbit-
HRP® (Dako, Glostrup, Denmark) for 30 minutes at room tem-
perature. Immunoreactivity was visualised by DAB+ reagent®
(Dako, Glostrup, Denmark).
Finally, sections were counter stained with Mayers acidic hae-
matoxylin for 12 seconds, dehydrated and mounted with per-
tex. Sections were rinsed carefully between each step with
TBS. This protocol is the result of an optimisation, as several
alternatives to each step have been thoroughly tested. The
Helix-II antibodies proved to be inappropriate for immunohisto-
chemistry on cartilage section from rats.
In situ hybridisation
A 261 bp cDNA fragment (bp 215-476, [Genbank:L48440])
of rat procollagen type IIα1 (exon 1) was synthesised with
flanking promoter regions for RNA polymerases T3 and T7 and
cloned into at pU57 cloning vector (GenScript, NJ, USA). The
plasmids containing the cDNA were linearised, and this served
as a template for the in vitro transcription of antisense and
sense riboprobes labelled with [α-33]-UTP (GE Healthcare,
Broendby, Denmark). Probes were DNAse treated and puri-
fied on a G50 column. In situ hybridisation was performed on
5 μm section of the decalcified and paraffin-embedded knees,
using a previously described procedure [30]. Briefly, the sec-
tions were digested in proteinase K, acetylated and incubated
with the riboprobes overnight at 55°C. The sections were then
treated with RNAse A and washed extensively. They were then
coated with LM-1 auto-radiographic emulsion (GE Healthcare,
Broendby, Denmark), exposed for up to four weeks and, devel-
oped and counterstained with H&E.
Statistics
The body and uterus weight at different time points were com-
pared with a one-way analysis of variance (ANOVA). The dif-
Table 1
Body and uterus weight of ovariectomised rats at baseline and at endpoint
Bodyweight (g) Uterus weight (mg)
Grp Subgrp n t = 0 t = 2 t = 6 Endpoint
A Sham 8 307.6 ± 37.2 303.0 ± 31.4 943.9 ± 247.3
OVX+ oestradiol 10 336.8 ± 32.6 282.0 ± 21.7* 1033.2 ± 288.2
OVX+ placebo 8 327.1 ± 30.6 340.0 ± 21.2 386.6 ± 100.7***
B Sham 8 323.4 ± 38.1 318.0 ± 33.6 318.8 ± 36.8 692.2 ± 151.7
OVX+ oestradiol 10 315.4 ± 20.6 270.5 ± 11.3*** 286.6 ± 10.5* 699.0 ± 133.3
OVX+ placebo 11 337.7 ± 30.4 351.2 ± 33.1* 373.3 ± 40.3** 287.3 ± 174.4***
Values are shown as mean ± SD. Significant levels calculated by Mann-Whitney U tests; * p < 0.05, ** p < 0.01 and *** p < 0.001. Time (t) is in 
weeks.Available online http://arthritis-research.com/content/11/1/R9
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ferences between biomarkers measured in pre- and
postmenopausal biomarkers were analysed by Mann-Whitney
U tests. The difference in a given biomarker at time point t = a
and time point t = 0 (baseline) was calculated in percent as fol-
lows:
(Xt = a - Xt = 0)/Xt = 0 * 100%,
where X is the measure obtained for the corresponding
marker.
The differences between treatments were analysed with a
one-way ANOVA (Turkey). Correlations between markers
were calculated by linear regression and values of Pearson's
correlation coefficient (r2) and the likelihood of non-zero slope
(p) is stated. Differences in Colombo score were compared by
Mann-Whitney U statistics. The relative frequency of positive
events by in situ hybridisation or immunohistochemistry in a
given experimental group was calculated by adding the
number of samples showing positive stainings at a specific
zone, and dividing this sum by the total number of samples in
this experimental group, to obtain a value of between 0 and 1.
Correlations between the level of serum/urinary markers and in
situ  hybridisation/immunohistochemistry were analysed by
Mann-Whitney U tests. For all statistical analysis, p < 0.05 was
considered significant: *p < 0.05, **p < 0.01 and ***p <
0.001.
Results
Measurement of CTX-II, Helix-II in pre- and 
postmenopausal women
Until now CTX-II was the only cartilage degradation marker
shown to be elevated in postmenopausal women. It was there-
fore interesting to investigate whether Helix-II would also be
elevated in postmenopausal women, and to what extent Helix-
II values would correlate with CTX-II. By assaying urine from
50 premenopausal and 50 postmenopausal women for the
degradation biomarkers Helix-II and CTX-II, we found that only
CTX-II was significantly increased in postmenopausal women
(Figure 2). Helix-II remained unchanged, and there was no cor-
relation between the two markers (r2 = 0.044, p = 0.663).
Thus, we reproduced the CTX-II response to menopause seen
by others [15,26], but did not find any indication for a
response of the other type II collagen degradation marker,
Helix-II.
Changes in body and uterus weight of the 
ovariectomised rats
To investigate the initial effects of oestrogen deficiency on car-
tilage in a more controlled way than in postmenopausal
women, we used an ovariectomy rat model, which has been
previously described as a model of postmenopausal OA
[17,26,31]. To determine the efficiency of the ovariectomy, the
uterus of all euthanased rats was weighed: all OVX+placebo
rats, in both groups A and B, had a significantly lower uterus
weight after two and six weeks. Furthermore, all OVX+oestra-
diol rats had a high uterus weight, which indicated that the
oestradiol implants had the desired compensatory effect
(Table 1). As expected, ovariectomy (OVX+placebo) induced
weight gain, whereas ovariectomised rats with oestradiol
implants (OVX+oestradiol) had a loss of body weight two to
six weeks after ovariectomy (Table 1). The sham-operated rats
did not show any change in weight through the two to six
weeks post-ovariectomy. In order to investigate whether ova-
riectomy-induced weight gain was associated with oestradiol
production, we measured serum oestradiol levels at different
times post-ovariectomy, but most samples showed values
below the detection limit (data not shown).
The serum or urinary levels of Helix-II, CTX-II and PIIANP 
in ovariectomised rats
We measured the levels of type II collagen degradation mark-
ers, serum Helix-II and urinary CTX-II, at time 0 and week 2 in
group A, and at time 0, and weeks 4 and 6 of group B. We
Figure 2
Measurement of urinary levels of (a) Helix-II and (b) CTX-II in pre- and  post-menopausal women Measurement of urinary levels of (a) Helix-II and (b) CTX-II in pre- and 
post-menopausal women. The values are corrected for creatinine. n = 
50 in the respective populations. Bars indicate the 95% range and out-
liers are shown as dots. The difference between the two populations 
was compared by Mann-Whitney U tests.Arthritis Research & Therapy    Vol 11 No 1    Bay-Jensen et al.
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found a significantly increased level of CTX-II after two and
four weeks in the OVX+placebo subgroups but not in the
Sham and OVX+oestradiol groups. This increased level drops
to baseline six weeks after ovariectomy (Figure 3b). The differ-
ence between OVX+placebo and OVX+oestradiol is still sig-
nificant after six weeks (Figure 3b). Taken together, these data
show that we could reproduce the CTX-II profiles obtained
previously [17]: that CTX-II is significantly elevated two and
four weeks after ovariectomy, but decreases to baseline after
six weeks, and is maintained at a low level if the ovariectomy
rats receive oestrogen. Interestingly, in contrast to CTX-II,
Helix-II levels did not change significantly with time in response
to ovariectomy, and were not statistically different from the
Helix-II levels in the Sham and OVX+placebo subgroups (Fig-
ure 3b). Neither was there any correlation between CTX-II and
Helix-II when the complete set of samples taken at the different
time points was analysed (r2 = 0.016, p = 0.344).
Next, we examined whether the increased CTX-II levels relate
to an increased type II collagen synthesis in the rats and there-
fore measured the synthesis marker PIIANP. Serum levels for
PIIANP did not change significantly over the six-week time
course: its levels were more or less the same throughout the
weeks and irrespectively of treatment (Figure 3c). There are no
correlations between the levels of urinary CTX-II or serum
Helix-II and serum PIIANP (r2 = 0.043, P = 0.117). Our rat ova-
riectomy experiments therefore show that oestrogen depriva-
tion transiently affects CTX-II levels as shown previously, but
did not provide evidence for an effect on Helix-II and PIIANP.
Histopathological approaches
We examined whether increased levels of CTX-II in body fluids
are reflected at the level of the knee joint. First, we analysed
the medial tibia plateau and the surrounding areas two and six
weeks after ovariectomy, because this was the prevailing area
showing alterations nine weeks after ovariectomy [17,26]. At
these earlier time points of the present experiment, however,
only mild alterations such as ulceration of the superficial sur-
face, loss of superficial layers, proteoglycan loss and cluster
formation were observed. More rats showed the latter two fea-
tures at the six-week time point, but there was no significant
difference between Sham, OVX+oestradiol or OVX+placebo
rats. We concluded that there is no apparent effect of ovariec-
tomy on histology six weeks post-surgery.
Second, we investigated whether CTX-II immunoreactivity was
present, in which area of the medial tibia, and whether its pres-
ence related to the experimental condition. Figure 4(a) to 4(d)
shows typical examples of how CTX-II immunoreactivity
appears in the different areas of the cartilage, as defined in
Figure 5. These include stainings immediately around
chondrocytes as well as further away in the matrix and at the
surface of areas where mechanical challenge is expected, but
also away from such areas like in the inner zone and in the
fibrocartilage of the margin zone.
Figure 3
Measurement of type II collagen markers Helix-II, CTX-II, and PIIANP in  ovariectomised rats Measurement of type II collagen markers Helix-II, CTX-II, and PIIANP in 
ovariectomised rats. The percentage difference from baseline value 
(time (t) = 0) is shown for each rat treated with sham (white boxes), 
OVX+oestradiol (grey boxes), OVX+placebo (black boxes). (a) Serum 
levels of Helix-II; (b) urinary levels of CTX-II; (c) serum levels of PIIANP. 
Bars represent median values. The mean (standard deviation) baseline 
levels of Helix-II, CTX-II and PIIANP were 8.69 (6.48) ng/ml, 1675 
(636.4) μg/mmol creatinine and 324.0 (141.4) ng/ml, respectively. The 
95% range is indicated by the bars. Changes induced as a function of 
time were compared with each other and treatments were compared by 
one-way analysis of variance, where *p < 0.05 and ** p < 0.01.Available online http://arthritis-research.com/content/11/1/R9
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In order to investigate the effect of oestrogen deprivation on
CTX-II immunostaining, in each of these zones we analysed
how frequently it was detected in the different rats (Figure 6).
The cartilage of none of the rats from the two-week group
showed CTX-II immunoreactivity at the margin and inner zone.
Only a few showed signals in the upper zone and in the growth
plate, but half of them showed signals in the deep zone (Figure
6a). Ovariectomised rats were more frequently positive in all
these cartilage areas, except at the level of the growth plate.
This increase in frequency was, however, smaller when these
ovariectomised rats were treated with oestrogen, except in the
inner and deep zones (Figure 6a). Overall, this analysis shows
that it is only at the level of upper and marginal zones that the
immunostainings reflected the pattern of urinary levels of CTX-
II in the experimental groups. The cartilage of the rats from the
six-week group tended to show less frequently CTX-II immuno-
reactivity compared with the two-week group, and the varia-
tions between the different experimental groups tended to
become smaller, which is also reminiscent of behaviour of the
urinary levels of CTX-II in these respective groups (Figure 6b).
Despite the latter parallel seen when comparing the experi-
mental groups, an analysis at the level of individual rats did not
show significant correlations between urinary CTX-II and
Figure 4
Illustrative examples of immunostainigs of CTX-II and PIIANP and in situ hybridisations of type IIA collagen mRNA Illustrative examples of immunostainigs of CTX-II and PIIANP and in situ hybridisations of type IIA collagen mRNA. All immunohistochemistry sec-
tions were stained with DAB+ (brown) and counterstained with Mayers acidic haematoxylin (blue). In situ hybridisations were developed with silver 
grains (black) and counterstained with H&E staining. CTX-II immunoreactivity was observed (a) around chondrocytes at the inner zone, (b) at super-
ficial matrix of the upper zone, (c) around the round and flat chondrocytes of the upper and deep zone and (d) in the growth plate. PIIANP immuno-
reactivity was observed (e) around and within the lacunas of the inner zone, (f) in the superficial matrix of a section and (g) in the proliferating cells 
of the growth plate. (h) Preimmune serum control for CTX-II at the growth plate (PIIANP preimmune showed similar results, data not shown). Col IIA 
mRNA expression was observed (i) in the inner zone, (j) in the middle of a section showing the upper and deep zone, (k) in the proliferating 
chondrocytes of the growth plate. (l) Negative control using Col IIA sense probe. All sections were captured at ×20 magnification.Arthritis Research & Therapy    Vol 11 No 1    Bay-Jensen et al.
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immunoreactivity in the tissue (e.g. at the upper zone p =
0.211 or at the deep zone p = 0.578).
It is not known whether CTX-II reflects degradation of pre-
existing cartilage matrix, and/or of newly synthesised collagen.
Thus, although the biochemical marker of collagen synthesis,
PIIANP, did not indicate any influence of oestrogen depriva-
tion, we also assessed collagen synthesis locally in cartilage
tissue, both through PIIANP immunoreactivity (Figures 5e to
5h) and in situ hybridisation for type II collagen (Figures 5i to
5l), and investigated to what extent these signals would reflect
CTX-II immunoreactivity in the tissue and correlate with the uri-
nary levels of CTX-II (Figure 7). Type II collagen mRNA was
found in all the cartilage areas of almost all the rats, and did not
vary much according to the oestrogen status, except for the
upper and margin areas, where it reflected the variations of
CTX-II immunoreactivity in the different experimental condi-
tions (Figure 7). Of these two zones, it is only in the upper zone
that the mRNA showed a significant correlation with the uri-
nary levels of CTX-II (p = 0.030 versus p = 0.943). PIIANP
occurred less frequently compared with type II collagen
mRNA, and was affected by oestrogen only at the level of the
margin zone, which is also the only area where it parallels CTX-
II (Figure 7). Our analysis did not indicate any significant cor-
relation between PIIANP immunoreactivity in the tissue, what-
ever the zone, and urinary CTX-II (all zones; p > 0.05).
Discussion
The hypothesis that oestrogen deficiency affects collagen
turnover in cartilage, is supported to a large extent by meas-
Figure 5
Description of the zones of interest for immunolocalisation and in situ hybridisation analysis Description of the zones of interest for immunolocalisation and in situ hybridisation analysis. The picture shows a medial tibia plateau and surround-
ings including the underlying growth plate. The knee is separated into five zones, which are circled and described on the right. The inner zone of the 
tibia is defined as the area where the articular cartilage turns downwards into the space between the lateral and medial plateaus.
Figure 6
Effect of treatment on the frequency of CTX-II immunoreactivity within the zones of interest two and six weeks after ovariectomy Effect of treatment on the frequency of CTX-II immunoreactivity within the zones of interest two and six weeks after ovariectomy. Numbers in each 
bar indicate the number of rats investigated.Available online http://arthritis-research.com/content/11/1/R9
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urements of a single marker, CTX-II, which responds to oestro-
gen status in a series of studies [16,17,26,32]. The present
study demonstrates that body fluid levels of two other markers
of type II collagen turnover did not respond to oestrogen defi-
ciency, whether in ovariectomised rats and/or postmenopau-
sal women. These other markers consisted in another type II
collagen degradation marker, Helix-II [20], and a marker of col-
lagen synthesis, PIIANP [22]. Interestingly, a recent report
extends our observations to a third type II collagen degrada-
tion marker, C2C, which does not respond to oestrogen defi-
ciency induced by menopause [33].
Situations where CTX-II shows a distinct behaviour compared
with Helix-II and PIIANP have already been reported. For exam-
ple, in OA all three markers are affected, but do not correlate
strongly when analysed at the level of individual patients
[20,24]. Immunostaining studies of OA cartilage have further
established that to some degree they show differential selec-
tivity for specific features into cartilage tissue [21]. Further-
more, it should be mentioned that CTX-II and Helix-II originate
from the telopeptide and helicoidal domain of type II collagen,
respectively, and that different proteinases were reported to
be involved in their generation [34]. Therefore, the differences
in behaviour between these two markers has been ascribed to
histological or time-related differences in proteinase expres-
sion [21]. Overall, there are a series of situations where CTX-
II behaves distinctly to other markers. The present study adds
to these series the unique response of CTX-II to oestrogen
deficiency.
There are many possible reasons why CTX-II is unique in its
response to oestrogen deficiency. First, it may be speculated
that oestrogen deprivation favours the proteolytic pathway
generating CTX-II, compared with the one generating Helix-II
[34]. The basis of this speculation is that oestrogens are
known regulators of the proteinases that are critical for carti-
lage collagenolysis [35,36]. As a matter of fact, oestrogens
were shown to determine the collagenolytic pathways used by
osteoclasts to degrade bone [37,38]. Of note, C2C, the type
II collagen degradation marker, which was recently reported to
not respond to menopause, originates from the helix domain-
like Helix-II [33].
Second, it has been proposed that distinct responses of mark-
ers to oestrogen reflect measurements of activities at different
sites in the cartilage [33]. Our CTX-II immunostaining fre-
quency analysis indeed indicates that specific areas of knee
cartilage do not respond to oestrogen deficiency, whereas
others do. Areas where CTX-II immunoreactivity did not
respond to oestrogen status, but was frequent, included the
deep and inner zone and growth plate, which is an area of high
collagen turnover, and was previously considered to be a pos-
sible key contributor to urinary CTX-II [17]. It has been specu-
lated that there is a relation between CTX-II and subchondral
bone events [21,33]. The basis of this speculation was that
both CTX-II and bone resorption are affected by oestrogen
[16,26,32] and by a series of bone resorption inhibitors
[18,39] and that the prevailing position in cartilage tissue of
CTX-II is at the bone-cartilage interface [21]. However, the lat-
ter immunohistochemical study was performed in OA carti-
Figure 7
Effect of treatment on the frequency of type IIA collagen mRNA expression and PIIANP immunostaining compared with CTX-II immunostaining Effect of treatment on the frequency of type IIA collagen mRNA expression and PIIANP immunostaining compared with CTX-II immunostaining. Num-
bers in each bar indicate the number of rats investigated. (a) CTX-II immunohistochemistry (IHC); (b) type IIA collagen (Col II) in situ hybridisation 
(IHC); (c) PIIANP IHC.Arthritis Research & Therapy    Vol 11 No 1    Bay-Jensen et al.
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lage, and the present frequency analysis of CTX-II
immunoreactivity in response to oestrogen status did not sup-
port this hypothesis, even if CTX-II was sometimes detected at
this level as previously reported in rat knees [40].
In contrast, the present study shows that the CTX-II immuno-
reactivity response to oestrogen status in the upper and mar-
gin zone is similar to that of urinary CTX-II. This is compatible
with a contribution of these zones to urinary CTX-II. Of note is
that the upper zone is also the area where mild erosion
appeared more frequently nine weeks after ovariectomy [17].
CTX-II immunoreactivity in this area was associated with ero-
sion both in the present and in our earlier study [31]. However
in the previous study, this CTX-II immunoreactivity detected
nine weeks after ovariectomy was not analysed statistically.
Therefore, it could not be related to ovariectomy-induced
changes in urinary levels of CTX-II, because these changes
occur only transiently and the CTX-II levels decreased to those
of sham-operated rats at this nine-week time point. In order to
relate oestrogen-induced changes in urinary levels of CTX-II to
immunoreactivity frequencies at the cartilage level, our study
was performed earlier after ovariectomy that is at the six-week
time point. However, we did not obtain evidence for oestro-
gen-related lesions at these early time points, and rats show-
ing immunoreactivity in the upper and margin zone were not
necessarily those with high urinary CTX-II, questioning there-
fore to what extent this area contributes effectively to oestro-
gen changes in urinary CTX-II levels. Anyway, a limitation of
these analyses is that they are restricted to knee cartilage
when many other joints may contribute to CTX-II production in
urine. As a matter of fact, the spine was proposed to be a
major contributor in postmenopausal women [41,42]. In con-
clusion, our histological analysis of CTX-II indicates that the
response of CTX-II to oestrogen status at the level of the
medial tibia specifically concerns the upper and margin zone.
The interesting question of whether this specific position dif-
ferentiates CTX-II from Helix-II could not be assessed,
because antibodies appropriate for immunohistochemistry of
Helix-II in rat tissue were not available.
Our study relates the cartilage areas where CTX-II is detected
most frequently with the areas where collagen synthesis
occurs. It has been previously reported that not only collagen
degradation, but also collagen synthesis is stimulated at least
at some stage of OA [5]. It has been proposed that rapid deg-
radation of newly synthesised collagen contributes to generat-
ing collagen fragments [43] and one may speculate that this
degradation of newly synthesised collagen contributes une-
qually to the generation of CTX-II and Helix-II. Our study dem-
onstrates active collagen synthesis whether evaluated through
mRNA or PIIANP. Interestingly, the zones where synthesis
responded to oestrogen were the upper and margin zones, like
for the CTX-II immunostainings. However, they were probably
too small to be reflected at the level of serum, and correlation
studies at the level of individual rats did not support the
hypothesis that oestrogen-induced changes in urinary levels of
CTX-II originate from degradation of newly synthesised colla-
gen.
Another important aspect of elevated urinary levels of CTX-II in
response to oestrogen deprivation is that it is transient,
because it returns to sham levels six to nine weeks after the
ovariectomy, depending on the experiments [17,31]. The
present study indicates the same tendency at the tissue level.
A possible explanation for this is oestrogen production by adi-
pose tissue, which acts locally in a paracrine/autocrine fash-
ion, leading to locally high concentrations [44].
Ovariectomised rats increase their body weight with time com-
pared with sham-operated rats, which means that the adipose
tissue mass increases and therefore also possibly the release
of oestrogen from adipose tissue increases. We speculate
that the latter may compensate to some extent for the lack of
ovarian oestrogen and attenuate progressively the elevation of
CTX-II. However, oestrogen levels were below the detection
limit, and therefore this hypothesis could not be verified. In
addition, it might be of interest to investigate whether the tran-
sient ovariectomy-induced increase in CTX-II is related to ova-
riectomy-induced down-regulation of eNOS [45] (Figure 8).
Indeed it is intriguing that both transient effects show similar
kinetics, and that eNOS induces a decrease in matrix metallo-
proteinase activity [46], which are the proteinases responsible
for CTX-II release [33]. Furthermore, oestrogen induces both
an increase in eNOS and a decrease in MMP activity in
chondrocytes [6].
Figure 8
Selective effect of oestrogen on one of the two pathways for type II col- lagen breakdown Selective effect of oestrogen on one of the two pathways for type II col-
lagen breakdown. The evidence for two type II collagenolytic mecha-
nisms, one related to cysteine proteinases and Helix-II, the other related 
to matrix metalloproteinase (MMPs) and CTX-II comes from Charni and 
colleagues [34]. The evidence for the selective effect of oestrogen on 
mechanism two comes from the present study. The evidence for the 
association of mechanism two with eNOS comes from Sniekers and 
colleagues [6], Grassi and colleagues [45] and Gurjar and colleagues 
[46].Available online http://arthritis-research.com/content/11/1/R9
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Conclusion
Our study demonstrates that oestrogen deficiency affects car-
tilage; however, only to a limited extent compared with what is
seen in OA. We propose that oestrogen deficiency specifically
affects the collagenolytic pathway that leads to a transient
increase in urinary levels of CTX-II and later to mild alterations
of the cartilage surface, but it does not significantly affect the
pathway that generates Helix-II or C2C [33] (Figure 8).
Although to some extent oestrogen affects collagen synthesis
at the level of cartilage, it was not significantly reflected by
changes in the urinary levels of PIIANP. Therefore, CTX-II
appears as a marker able to detect early alterations after oes-
trogen deprivation that other markers cannot detect in a sensi-
tive way.
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